25.02.2014 Fresenius SE & Co. KGaA  DE0005785604

DGAP-Adhoc: Fresenius SE & Co. KGaA: Fiscal year 2013: Group net income at top end of guidance, exceeding EUR1 billion - Positive Group outlook for 2014


 
Fresenius SE & Co. KGaA / Key word(s): Final Results 25.02.2014 07:00 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fiscal year 2013: Group net income at top end of guidance, exceeding EUR1 billion - Positive Group outlook for 2014 In 2013, Group sales increased by 5% (constant currency: 8%) to EUR20,331 million (2012: EUR19,290 million. Organic sales growth was 4%. Acquisitions contributed 5%. Divestitures reduced sales growth by 1%. Currency translation had a negative effect of 3%. Group EBIT* was EUR3,045 million, an increase of 1% in constant currency (2012: EUR3,075 million). The EBIT margin was 15.0% (2012: 15.9%). Group net income** increased by 12% (14% in constant currency) to EUR1,051 million (2012: EUR938 million). Earnings per share** increased by 8% to EUR5.88 (2012: EUR5.42). Group net income attributable to shareholders of Fresenius SE & Co. KGaA including Fenwal integration costs was EUR1,011 million or EUR5.66 per share. Based on the strong financial results, the Management Board will propose to the Supervisory Board a dividend increase of 14 % to EUR1.25 per share (2012: EUR1.10). The total dividend distribution is expected to be EUR225 million. For 2014, Fresenius projects sales growth of 12% to 15% in constant currency. Net income*** is expected to increase by 2% to 5% in constant currency. The Group's U.S. GAAP financial results as of December 31, 2013 are adjusted for Fenwal integration costs. Adjusted earnings represent the Group's business operations in the reporting period. * 2013 before Fenwal integration costs (EUR54 million); 2012 before one-time effects ** Net income attributable to shareholders of Fresenius SE & Co. KGaA ; 2013 before integration costs for Fenwal (EUR40 million); 2012 before one-time effects *** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2014 before integration costs for Fenwal (EUR30-40 million) and the hospitals acquired from Rhön-Klinikum AG (vast majority of ~EUR65 million in total); 2013 before Fenwal integration costs (EUR40 million) The 2014 guidance includes contributions from the acquisition of hospitals from Rhön-Klinikum AG. (Financial statements according to U.S. GAAP) Fresenius SE & Co. KGaA, represented by Fresenius Management SE, Board of Management Bad Homburg v.d.H., February 25, 2014 End of note 25.02.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: [email protected] Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard), München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart; Terminbörse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 29.083,00 33.530,00 35.409,00 37.250,00 36.277,00 38.090,00 0,00
EBITDA1,2 5.500,00 6.267,00 6.032,00 7.083,00 7.132,00 0,00 0,00
EBITDA-Marge3 18,91 18,69 17,04 19,01 19,66 0,00 0,00
EBIT1,4 4.327,00 4.589,00 5.251,00 4.631,00 4.385,00 0,00 0,00
EBIT-Marge5 14,88 13,69 14,83 12,43 12,09 0,00 0,00
Jahresüberschuss1 2.676,00 1.816,00 1.871,00 1.915,00 2.823,00 2.960,00 0,00
Netto-Marge6 9,20 5,42 5,28 5,14 7,78 7,77 0,00
Cashflow1,7 3.574,00 3.937,00 3.742,00 4.263,00 6.549,00 0,00 0,00
Ergebnis je Aktie8 2,83 3,25 3,37 3,44 3,06 3,25 3,60
Dividende8 0,62 0,75 0,80 0,84 0,88 0,92 0,96
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

XETR:FRE Charts by TradingView (c)


INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 36,345 Kaufen 20.298,76
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
9,32 17,43 0,53 13,19
KBV KCV KUV EV/EBITDA
1,14 3,10 0,56 6,22
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,88 0,92 2,53 13.05.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
04.05.2022 02.08.2022 02.11.2021 22.02.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,63% -11,56% 2,67% -4,81%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei DGAP abrufen


Medtech , 578560 , FRE , XETR:FRE